<DOC>
	<DOCNO>NCT01007383</DOCNO>
	<brief_summary>The purpose first-in-man trial determine safety tolerability ascend single multiple dos LEO 27847 healthy male subject . The trial perform two part . In Part 1 , single dos LEO 27847 administer healthy male subject . In Part 2 , multiple dos LEO 27847 administer healthy male subject .</brief_summary>
	<brief_title>LEO 27847 - A Study Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Subjects male 18 45 year age , body mass index ( BMI ) 18 32 kg/m2 inclusive . Subjects minimum weight 50 kg Subjects must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation ( congenital nonhaemolytic hyperbilirubinaemia acceptable ) Subjects give write informed consent participate study abide study restriction Male subject willing use appropriate contraception ( condom ) female partner ; occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository ) time first dose 3 month final dosing occasion . Subjects receive prescribed systemic topical medication within 7 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety Subjects receive medication , include St John 's Wort , know chronically alter drug absorption elimination process within 30 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety Subjects still participate clinical study ( e.g . attend followup visit ) participate clinical study involve administration investigational drug ( new chemical entity ) , market drug within past 3 month prior first dose occasion . Subjects donate blood , plasma platelet month prior screen make donation two occasion within 12 month precede first dose administration Subjects significant history drug allergy determine Investigator Subjects clinically significant allergic disease ( exclude nonactive hayfever ) determine Investigator Subjects supine blood pressure supine pulse rate screen high 140/90 mmHg 100 beat per minute ( bpm ) , respectively , low 90/50 mmHg 50 bpm , respectively . Healthy young male pulse rate 45 50 bpm may include discretion investigator . Subjects consume 28 unit ( male ) alcohol per week significant history alcoholism drug/chemical abuse determine Investigator ( one unit alcohol equal Â½ pint [ 285 mL ] beer lager , one glass [ 125 mL ] wine , 1/6 gill [ 25 mL ] spirit ) Subjects smoke 15 cigarette equivalent tobacco per day Subjects , history , clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , haematological , dermatological major disorder determine Investigator Subjects clinically significant illness within 4 week start dose administration determine Investigator Subjects know hepatitis , carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody , positive result test HIV antibodies Subjects , opinion General Practitioner ( GP ) Investigator , participate study , include subject suspect whatever reason able comply requirement protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Safety tolerability LEO 27847</keyword>
</DOC>